Advanced Biomed Inc. Common Stock Total Liabilities
Advanced Biomed Inc. Common Stock total liabilities. Based on the latest financial reports, Advanced Biomed Inc. Common Stock (ADVB) has total liabilities worth $1.44 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See operational self-sufficiency of Advanced Biomed Inc. Common Stock to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Advanced Biomed Inc. Common Stock (2021–2025)
Total liabilities of Advanced Biomed Inc. Common Stock from 2021 to 2025. This chart illustrates how Advanced Biomed Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check Advanced Biomed Inc. Common Stock liquidity resilience to evaluate the company's liquid asset resilience ratio.
Advanced Biomed Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Advanced Biomed Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Solo Brands, Inc.
NYSE:SBDS
|
USA | $316.38 Million |
|
Combigene AB
ST:COMBI
|
Sweden | Skr4.30 Million |
|
Aqua Metals Inc
NASDAQ:AQMS
|
USA | $3.09 Million |
|
X2M Connect Ltd
AU:X2M
|
Australia | AU$9.26 Million |
|
Shiva Mills Limited
NSE:SHIVAMILLS
|
India | Rs-924.96 Million |
|
Oscar Mitra Sukses Sejahtera Tbk PT
JK:OLIV
|
Indonesia | Rp732.11 Million |
|
Korea SE Corp
KQ:101670
|
Korea | ₩16.53 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down Advanced Biomed Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Advanced Biomed Inc. Common Stock asset portfolio.
Liquidity & Leverage Metrics
Advanced Biomed Inc. Common Stock Total Liabilities Ratios Explained
Advanced Biomed Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Advanced Biomed Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Advanced Biomed Inc. Common Stock (2021–2025)
The table below shows the annual total liabilities of Advanced Biomed Inc. Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $3.03 Million | +8.50% |
| 2024-06-30 | $2.80 Million | -15.10% |
| 2023-06-30 | $3.29 Million | +2.25% |
| 2022-06-30 | $3.22 Million | +10592.98% |
| 2021-06-30 | $30.13K | -- |
About Advanced Biomed Inc. Common Stock
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagul… Read more